Valproic acid inhibits ATP-triggered Ca2+release via a p38-dependent mechanism in bEND.3 endothelial cells

Iat Lon Leong, Tien Yao Tsai, Kar Lok Wong, Lian Ru Shiao, Ka Shun Cheng, Paul Chan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

© 2018 Société Française de Pharmacologie et de Thérapeutique Valproic acid (VA) is currently used to treat epilepsy and bipolar disorder. It has also been demonstrated to promote neuroprotection and neurogenesis. Although beneficial actions of VA on brain blood vessels have also been demonstrated, the effects of VA on brain endothelial cell (EC) Ca2+signaling are hitherto unreported. In this report, we examined the effects of VA on agonist-triggered Ca2+signaling in mouse cortical bEND.3 EC. While VA (100 μm) did not cause an acute inhibition of ATP-triggered Ca2+signaling, a 30-min VA treatment strongly suppressed ATP-triggered intracellular Ca2+release; however, such treatment did not affect Ca2+release triggered by cyclopiazonic acid, an inhibitor of SERCA Ca2+pump, suggesting there was no reduction in Ca2+store size. VA-activated p38 signaling, and VA-induced inhibition of ATP-triggered Ca2+release was prevented by SB203580, a p38 inhibitor, suggesting VA caused the inhibition by activating p38. Remarkably, VA treatment did not affect acetylcholine-triggered Ca2+release, suggesting VA may not inhibit inositol 1,4,5-trisphosphate-induced Ca2+release per se, and may not act directly on Gq or phospholipase C. Taken together, our results suggest VA treatment, via a p38-dependent mechanism, led to an inhibition of purinergic receptor-effector coupling.
Original languageEnglish
Pages (from-to)499-506
Number of pages8
JournalFundamental and Clinical Pharmacology
Volume32
Issue number5
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Valproic Acid
Endothelial Cells
Adenosine Triphosphate
Purinergic Receptors
Inositol 1,4,5-Trisphosphate
Neurogenesis
Brain
Type C Phospholipases
Bipolar Disorder
Acetylcholine
Blood Vessels
Epilepsy

Keywords

  • Ca release 2+
  • endothelial cells
  • p38
  • purinergic receptor
  • valproic acid

Cite this

Valproic acid inhibits ATP-triggered Ca2+release via a p38-dependent mechanism in bEND.3 endothelial cells. / Leong, Iat Lon; Tsai, Tien Yao; Wong, Kar Lok; Shiao, Lian Ru; Cheng, Ka Shun; Chan, Paul.

In: Fundamental and Clinical Pharmacology, Vol. 32, No. 5, 01.10.2018, p. 499-506.

Research output: Contribution to journalArticle

Leong, Iat Lon ; Tsai, Tien Yao ; Wong, Kar Lok ; Shiao, Lian Ru ; Cheng, Ka Shun ; Chan, Paul. / Valproic acid inhibits ATP-triggered Ca2+release via a p38-dependent mechanism in bEND.3 endothelial cells. In: Fundamental and Clinical Pharmacology. 2018 ; Vol. 32, No. 5. pp. 499-506.
@article{e8f047b9c16049818b846d3be790d495,
title = "Valproic acid inhibits ATP-triggered Ca2+release via a p38-dependent mechanism in bEND.3 endothelial cells",
abstract = "{\circledC} 2018 Soci{\'e}t{\'e} Fran{\cc}aise de Pharmacologie et de Th{\'e}rapeutique Valproic acid (VA) is currently used to treat epilepsy and bipolar disorder. It has also been demonstrated to promote neuroprotection and neurogenesis. Although beneficial actions of VA on brain blood vessels have also been demonstrated, the effects of VA on brain endothelial cell (EC) Ca2+signaling are hitherto unreported. In this report, we examined the effects of VA on agonist-triggered Ca2+signaling in mouse cortical bEND.3 EC. While VA (100 μm) did not cause an acute inhibition of ATP-triggered Ca2+signaling, a 30-min VA treatment strongly suppressed ATP-triggered intracellular Ca2+release; however, such treatment did not affect Ca2+release triggered by cyclopiazonic acid, an inhibitor of SERCA Ca2+pump, suggesting there was no reduction in Ca2+store size. VA-activated p38 signaling, and VA-induced inhibition of ATP-triggered Ca2+release was prevented by SB203580, a p38 inhibitor, suggesting VA caused the inhibition by activating p38. Remarkably, VA treatment did not affect acetylcholine-triggered Ca2+release, suggesting VA may not inhibit inositol 1,4,5-trisphosphate-induced Ca2+release per se, and may not act directly on Gq or phospholipase C. Taken together, our results suggest VA treatment, via a p38-dependent mechanism, led to an inhibition of purinergic receptor-effector coupling.",
keywords = "Ca release 2+, endothelial cells, p38, purinergic receptor, valproic acid",
author = "Leong, {Iat Lon} and Tsai, {Tien Yao} and Wong, {Kar Lok} and Shiao, {Lian Ru} and Cheng, {Ka Shun} and Paul Chan",
year = "2018",
month = "10",
day = "1",
doi = "10.1111/fcp.12381",
language = "English",
volume = "32",
pages = "499--506",
journal = "Fundamental and Clinical Pharmacology",
issn = "0767-3981",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Valproic acid inhibits ATP-triggered Ca2+release via a p38-dependent mechanism in bEND.3 endothelial cells

AU - Leong, Iat Lon

AU - Tsai, Tien Yao

AU - Wong, Kar Lok

AU - Shiao, Lian Ru

AU - Cheng, Ka Shun

AU - Chan, Paul

PY - 2018/10/1

Y1 - 2018/10/1

N2 - © 2018 Société Française de Pharmacologie et de Thérapeutique Valproic acid (VA) is currently used to treat epilepsy and bipolar disorder. It has also been demonstrated to promote neuroprotection and neurogenesis. Although beneficial actions of VA on brain blood vessels have also been demonstrated, the effects of VA on brain endothelial cell (EC) Ca2+signaling are hitherto unreported. In this report, we examined the effects of VA on agonist-triggered Ca2+signaling in mouse cortical bEND.3 EC. While VA (100 μm) did not cause an acute inhibition of ATP-triggered Ca2+signaling, a 30-min VA treatment strongly suppressed ATP-triggered intracellular Ca2+release; however, such treatment did not affect Ca2+release triggered by cyclopiazonic acid, an inhibitor of SERCA Ca2+pump, suggesting there was no reduction in Ca2+store size. VA-activated p38 signaling, and VA-induced inhibition of ATP-triggered Ca2+release was prevented by SB203580, a p38 inhibitor, suggesting VA caused the inhibition by activating p38. Remarkably, VA treatment did not affect acetylcholine-triggered Ca2+release, suggesting VA may not inhibit inositol 1,4,5-trisphosphate-induced Ca2+release per se, and may not act directly on Gq or phospholipase C. Taken together, our results suggest VA treatment, via a p38-dependent mechanism, led to an inhibition of purinergic receptor-effector coupling.

AB - © 2018 Société Française de Pharmacologie et de Thérapeutique Valproic acid (VA) is currently used to treat epilepsy and bipolar disorder. It has also been demonstrated to promote neuroprotection and neurogenesis. Although beneficial actions of VA on brain blood vessels have also been demonstrated, the effects of VA on brain endothelial cell (EC) Ca2+signaling are hitherto unreported. In this report, we examined the effects of VA on agonist-triggered Ca2+signaling in mouse cortical bEND.3 EC. While VA (100 μm) did not cause an acute inhibition of ATP-triggered Ca2+signaling, a 30-min VA treatment strongly suppressed ATP-triggered intracellular Ca2+release; however, such treatment did not affect Ca2+release triggered by cyclopiazonic acid, an inhibitor of SERCA Ca2+pump, suggesting there was no reduction in Ca2+store size. VA-activated p38 signaling, and VA-induced inhibition of ATP-triggered Ca2+release was prevented by SB203580, a p38 inhibitor, suggesting VA caused the inhibition by activating p38. Remarkably, VA treatment did not affect acetylcholine-triggered Ca2+release, suggesting VA may not inhibit inositol 1,4,5-trisphosphate-induced Ca2+release per se, and may not act directly on Gq or phospholipase C. Taken together, our results suggest VA treatment, via a p38-dependent mechanism, led to an inhibition of purinergic receptor-effector coupling.

KW - Ca release 2+

KW - endothelial cells

KW - p38

KW - purinergic receptor

KW - valproic acid

UR - http://www.scopus.com/inward/record.url?scp=85053200072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053200072&partnerID=8YFLogxK

U2 - 10.1111/fcp.12381

DO - 10.1111/fcp.12381

M3 - Article

C2 - 29752814

AN - SCOPUS:85053200072

VL - 32

SP - 499

EP - 506

JO - Fundamental and Clinical Pharmacology

JF - Fundamental and Clinical Pharmacology

SN - 0767-3981

IS - 5

ER -